Inspire is a medical technology company that develops and commercializes the Inspire system, a minimally invasive implantable neurostimulation device for treating moderate to severe obstructive sleep apnea by stimulating the hypoglossal nerve to maintain airway patency. The company sells its device through a direct sales force in the U.S. and select international markets, targeting sleep physicians and centers, and generates revenue from device implants supported by comprehensive reimbursement from commercial insurers, Medicare, and international payors. Inspire's competitive advantages include first-mover FDA approval as the only closed-loop hypoglossal nerve stimulation device, extensive peer-reviewed clinical evidence demonstrating sustained efficacy and high patient compliance, a proprietary patent portfolio, and established market access expertise across major geographies.